M&A Deal Summary |
|
|---|---|
| Date | 2019-11-27 |
| Target | 3D4Medical |
| Sector | Information Technology |
| Buyer(s) | Elsevier BV |
| Sellers(s) | Malin |
| Deal Type | Divestiture |
SEARCH BY
Try For Free 7-Day Free Trial
Elsevier is a publishing company which publishes medical and scientific information. The Company is based in Amsterdam with additional operations in the United Kingdom, US, Mexico, Brazil, and Spain.
| DEAL STATS | # |
|---|---|
| Overall | 24 of 29 |
| Sector (Information Technology) | 3 of 4 |
| Type (Divestiture) | 3 of 3 |
| Country (Ireland) | 1 of 1 |
| Year (2019) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-12-19 |
Science-Metrix
Montreal, Quebec, Canada Science-Metrix is a Canadian research evaluation firm specializing in the assessment of science and technology (S&T) activities. Founded in 2002, the firm is an internationally recognized leader in the assessment of S&T using bibliometric methods and in the evaluation of science-based programs and initiatives. Science-Metrix has successfully completed around 500 research and evaluation contracts for dozens of organizations across North America, Europe, Africa and the Middle East. Over the years, the firm has developed cutting-edge expertise in the development and production of R&I indicators for bibliometrics and technometrics, including gender-based indicators and the measurement of open access publications. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-03-11 |
Authess
Boston, Massachusetts, United States Authess is a developer of an advanced performance-based competency assessment platform that evaluates how students solve complex, open-ended problems they would encounter on the job. Authess was founded in 2015 and is based in Boston, Massachusetts. |
Buy | - |
| Category | Company |
|---|---|
| Founded | 2014 |
| Sector | Life Science |
| Employees | 255 |
| Revenue | 41M EUR (2020) |
Malin is a globally operating life sciences company. Malin was founded in 2014 and is based in Dublin, Ireland.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 6 |
| Sector (Information Technology) | 1 of 1 |
| Type (Divestiture) | 1 of 3 |
| Country (Ireland) | 1 of 3 |
| Year (2019) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-08-09 |
Melinta Therapeutics
New Haven, Connecticut, United States Melinta Therapeutics is a molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-07-09 |
Poseida Therapeutics
San Diego, California, United States Poseida Therapeutics is a therapeutics-focused biotechnology company using best-in-class genome engineering technologies to develop novel, life-saving treatments, including gene therapies for orphan liver diseases and immuno-oncology therapeutics for several types of cancer. Poseida's lead product candidates include a gene therapy treatment for the rare liver disease Progressive Familial Intraheptatic Cholestasis 3 and an autologous CAR-T therapeutic for multiple myeloma. Poseida is also partnered with Janssen Biotech (JNJ) to develop allogeneic CAR-T therapies for various cancers. Poseida owns several industry-leading technologies, including the piggyBac DNA Modification System, XTN TALEN and NextGEN CRISPR site-specific nucleases, and Footprint-Free Gene Editing (FFGE). Poseida Therapeutics was founded in 2014 and is based in San Diego, California. |
Sell | - |
